Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

The role of the c-Met pathway in lung cancer and the potential for targeted therapy.

Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R.

Ther Adv Med Oncol. 2011 Jul;3(4):171-84. doi: 10.1177/1758834011408636.

2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
3.

Role of HGF/MET axis in resistance of lung cancer to contemporary management.

Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr.

Transl Lung Cancer Res. 2012 Sep;1(3):179-93. doi: 10.3978/j.issn.2218-6751.2012.09.04. Review.

4.

The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.

Robinson KW, Sandler AB.

Oncologist. 2013;18(2):115-22. doi: 10.1634/theoncologist.2012-0262. Epub 2013 Jan 23. Review.

5.

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.

Smyth EC, Sclafani F, Cunningham D.

Onco Targets Ther. 2014 Jun 12;7:1001-14. doi: 10.2147/OTT.S44941. eCollection 2014. Review.

6.

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib.

Agwa ES, Ma PC.

Cancer Manag Res. 2014 Oct 4;6:397-404. doi: 10.2147/CMAR.S37345. eCollection 2014. Review.

7.

MET inhibitors in combination with other therapies in non-small cell lung cancer.

Padda S, Neal JW, Wakelee HA.

Transl Lung Cancer Res. 2012 Dec;1(4):238-53. doi: 10.3978/j.issn.2218-6751.2012.10.08. Review.

8.

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.

Yano S, Takeuchi S, Nakagawa T, Yamada T.

Cancer Sci. 2012 Jul;103(7):1189-94. doi: 10.1111/j.1349-7006.2012.02279.x. Epub 2012 May 9. Review.

9.

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R.

Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59. Review.

PMID:
11750879
10.

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Sattler M, Salgia R.

Curr Oncol Rep. 2007 Mar;9(2):102-8. Review.

PMID:
17288874
11.

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Landi L, Minuti G, D'Incecco A, Cappuzzo F.

Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Review.

PMID:
23385860
12.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
13.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Review.

PMID:
24636263
14.

MET as a target for treatment of chest tumors.

Cipriani NA, Abidoye OO, Vokes E, Salgia R.

Lung Cancer. 2009 Feb;63(2):169-79. doi: 10.1016/j.lungcan.2008.06.011. Epub 2008 Jul 30. Review.

15.

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

Zorzetto M, Ferrari S, Saracino L, Inghilleri S, Stella GM.

Transl Lung Cancer Res. 2012 Sep;1(3):194-207. doi: 10.3978/j.issn.2218-6751.2012.09.03. Review.

16.

Biomarker development in MET-targeted therapy.

Zhang Y, Du Z, Zhang M.

Oncotarget. 2016 Mar 22. doi: 10.18632/oncotarget.8276. [Epub ahead of print] Review.

17.

The emerging role of MET/HGF inhibitors in oncology.

Scagliotti GV, Novello S, von Pawel J.

Cancer Treat Rev. 2013 Nov;39(7):793-801. doi: 10.1016/j.ctrv.2013.02.001. Epub 2013 Feb 28. Review.

PMID:
23453860
18.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Christensen JG, Burrows J, Salgia R.

Cancer Lett. 2005 Jul 8;225(1):1-26. Epub 2004 Nov 11. Review.

PMID:
15922853
19.

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T.

Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14. doi: 10.1007/s10555-012-9391-7. Review.

PMID:
22736441
20.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.

Chung C.

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8. Review.

PMID:
25855240
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk